4/10
11:19 am
syrs
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML [Yahoo! Finance]
Low
Report
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML [Yahoo! Finance]
4/10
10:22 am
syrs
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Low
Report
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]
4/9
07:15 am
syrs
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression [Yahoo! Finance]
High
Report
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression [Yahoo! Finance]
4/9
07:00 am
syrs
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
High
Report
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
4/5
02:08 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/3
12:11 pm
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $13.00 price target on the stock.
Low
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $13.00 price target on the stock.
4/2
04:30 pm
syrs
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/1
08:08 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
High
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
3/28
11:04 pm
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/28
10:09 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
07:38 am
syrs
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/27
07:30 am
syrs
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Medium
Report
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
3/25
07:05 am
syrs
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial [Yahoo! Finance]
Low
Report
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial [Yahoo! Finance]
3/25
07:00 am
syrs
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Low
Report
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
3/20
07:00 am
syrs
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Low
Report
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
3/12
11:02 pm
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/29
03:07 pm
syrs
Activist investor Jeff Ubben to join Bayer’s supervisory board [FT.com - Mergermarket]
Low
Report
Activist investor Jeff Ubben to join Bayer’s supervisory board [FT.com - Mergermarket]
2/27
07:00 am
syrs
Syros to Participate in TD Cowen 44th Annual Health Care Conference
Medium
Report
Syros to Participate in TD Cowen 44th Annual Health Care Conference
2/27
05:36 am
syrs
Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year [Yahoo! Finance]
Medium
Report
Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year [Yahoo! Finance]
2/16
01:08 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/13
07:34 pm
syrs
Treadwell Announces the Formation and Members of Scientific Advisory Board [Yahoo! Finance]
Low
Report
Treadwell Announces the Formation and Members of Scientific Advisory Board [Yahoo! Finance]
2/8
04:09 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
1/31
10:03 pm
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
1/23
10:06 pm
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
1/19
12:28 pm
syrs
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why [Yahoo! Finance]